Back

Novel epigenetic mapping in cell-free DNA for detection of changes during sodium glucose cotransporter 2 inhibitors (SGLT2I) treatment in heart failure patients

29 August 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - RNA biology, epigenetic modifications, and cardiovascular risk Genetics, Epigenetics, ncRNA ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Tamar Itach

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

8 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor K. Kokot (Leipzig, DE)
Abstract
Presentation thumbnail
Doctor H. Li (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Ms O. Bavuu (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Mr D. Bagues Castro (Oviedo, ES)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - RNA biology, epigenetic modifications, and cardiovascular risk

The Event

Event poster

ESC Congress 2025

29 August 2025 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Investigation of biomarker response to SGLT2 Inhibition in heart failure (SiN-HF)
thumbnail
Congress Session
Heart failure in the era of precision medicine: insights into pathophysiology and emerging treatments
thumbnail
Congress Presentation
Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in cancer patients: a systematic review and meta-analysis of heart failure hospitalisation and mortality.

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources